Genetic variation in
This study investigated polymorphisms of five inflammatory-related genes for association with duloxetine and placebo response in patients with major depression. Twenty SNPs in and were genotyped in major depressive disorder patients treated with either duloxetine (n = 215) or placebo (n = 235) for u...
Gespeichert in:
| Veröffentlicht in: | Pharmacogenomics 2015-11, Vol.16 (17), p.1919-1929 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1929 |
|---|---|
| container_issue | 17 |
| container_start_page | 1919 |
| container_title | Pharmacogenomics |
| container_volume | 16 |
| creator | Maciukiewicz, Malgorzata Marshe, Victoria S Tiwari, Arun K Fonseka, Trehani M Freeman, Natalie Rotzinger, Susan Foster, Jane A Kennedy, James L Kennedy, Sidney H Müller, Daniel J |
| description | This study investigated polymorphisms of five inflammatory-related genes for association with duloxetine and placebo response in patients with major depression.
Twenty SNPs in
and
were genotyped in major depressive disorder patients treated with either duloxetine (n = 215) or placebo (n = 235) for up to 8 weeks. Treatment response was measured with the Montgomery-Åsberg Depression Rating Scale.
variants rs2066992 and rs10242595 were nominally associated with response to duloxetine (p = 0.047 and p = 0.028, respectively). Notably, the variant rs2066992 was also associated with placebo response (p = 0.026). However, none of our results remained significant after correction for multiple testing.
Our findings tentatively suggest that
variants play a role in duloxetine and placebo response, which warrants further investigation. |
| doi_str_mv | 10.2217/pgs.15.136 |
| format | Article |
| fullrecord | <record><control><sourceid>futurescience</sourceid><recordid>TN_cdi_futurescience_futuremedicine_10_2217_pgs_15_136</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_2217_pgs_15_136</sourcerecordid><originalsourceid>FETCH-futurescience_futuremedicine_10_2217_pgs_15_1363</originalsourceid><addsrcrecordid>eNqdzk0KwjAQBeBBFKw_G_EAvUDSTJqm7sWfA7gPIU5lRKM0ree3oidw9d5bPPgAVqik1lgXz0uSWEks7QgyrI0RG2X0eOjGaqEN2inMUroqpdEalcH6QJE6DvnLt-w7fsSc4wImjb8lWv5yDna_O22Poum7vqUUmGIg9113OnPgSA6V-xjcYHBYucFQ_n18A3DFPLk</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Genetic variation in</title><source>PubMed Central</source><creator>Maciukiewicz, Malgorzata ; Marshe, Victoria S ; Tiwari, Arun K ; Fonseka, Trehani M ; Freeman, Natalie ; Rotzinger, Susan ; Foster, Jane A ; Kennedy, James L ; Kennedy, Sidney H ; Müller, Daniel J</creator><creatorcontrib>Maciukiewicz, Malgorzata ; Marshe, Victoria S ; Tiwari, Arun K ; Fonseka, Trehani M ; Freeman, Natalie ; Rotzinger, Susan ; Foster, Jane A ; Kennedy, James L ; Kennedy, Sidney H ; Müller, Daniel J</creatorcontrib><description>This study investigated polymorphisms of five inflammatory-related genes for association with duloxetine and placebo response in patients with major depression.
Twenty SNPs in
and
were genotyped in major depressive disorder patients treated with either duloxetine (n = 215) or placebo (n = 235) for up to 8 weeks. Treatment response was measured with the Montgomery-Åsberg Depression Rating Scale.
variants rs2066992 and rs10242595 were nominally associated with response to duloxetine (p = 0.047 and p = 0.028, respectively). Notably, the variant rs2066992 was also associated with placebo response (p = 0.026). However, none of our results remained significant after correction for multiple testing.
Our findings tentatively suggest that
variants play a role in duloxetine and placebo response, which warrants further investigation.</description><identifier>ISSN: 1462-2416</identifier><identifier>EISSN: 1744-8042</identifier><identifier>DOI: 10.2217/pgs.15.136</identifier><language>eng</language><publisher>Future Medicine Ltd</publisher><subject>cytokines ; depression ; duloxetine ; inflammation ; placebo ; treatment response</subject><ispartof>Pharmacogenomics, 2015-11, Vol.16 (17), p.1919-1929</ispartof><rights>Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Maciukiewicz, Malgorzata</creatorcontrib><creatorcontrib>Marshe, Victoria S</creatorcontrib><creatorcontrib>Tiwari, Arun K</creatorcontrib><creatorcontrib>Fonseka, Trehani M</creatorcontrib><creatorcontrib>Freeman, Natalie</creatorcontrib><creatorcontrib>Rotzinger, Susan</creatorcontrib><creatorcontrib>Foster, Jane A</creatorcontrib><creatorcontrib>Kennedy, James L</creatorcontrib><creatorcontrib>Kennedy, Sidney H</creatorcontrib><creatorcontrib>Müller, Daniel J</creatorcontrib><title>Genetic variation in</title><title>Pharmacogenomics</title><description>This study investigated polymorphisms of five inflammatory-related genes for association with duloxetine and placebo response in patients with major depression.
Twenty SNPs in
and
were genotyped in major depressive disorder patients treated with either duloxetine (n = 215) or placebo (n = 235) for up to 8 weeks. Treatment response was measured with the Montgomery-Åsberg Depression Rating Scale.
variants rs2066992 and rs10242595 were nominally associated with response to duloxetine (p = 0.047 and p = 0.028, respectively). Notably, the variant rs2066992 was also associated with placebo response (p = 0.026). However, none of our results remained significant after correction for multiple testing.
Our findings tentatively suggest that
variants play a role in duloxetine and placebo response, which warrants further investigation.</description><subject>cytokines</subject><subject>depression</subject><subject>duloxetine</subject><subject>inflammation</subject><subject>placebo</subject><subject>treatment response</subject><issn>1462-2416</issn><issn>1744-8042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqdzk0KwjAQBeBBFKw_G_EAvUDSTJqm7sWfA7gPIU5lRKM0ree3oidw9d5bPPgAVqik1lgXz0uSWEks7QgyrI0RG2X0eOjGaqEN2inMUroqpdEalcH6QJE6DvnLt-w7fsSc4wImjb8lWv5yDna_O22Poum7vqUUmGIg9113OnPgSA6V-xjcYHBYucFQ_n18A3DFPLk</recordid><startdate>20151101</startdate><enddate>20151101</enddate><creator>Maciukiewicz, Malgorzata</creator><creator>Marshe, Victoria S</creator><creator>Tiwari, Arun K</creator><creator>Fonseka, Trehani M</creator><creator>Freeman, Natalie</creator><creator>Rotzinger, Susan</creator><creator>Foster, Jane A</creator><creator>Kennedy, James L</creator><creator>Kennedy, Sidney H</creator><creator>Müller, Daniel J</creator><general>Future Medicine Ltd</general><scope/></search><sort><creationdate>20151101</creationdate><title>Genetic variation in</title><author>Maciukiewicz, Malgorzata ; Marshe, Victoria S ; Tiwari, Arun K ; Fonseka, Trehani M ; Freeman, Natalie ; Rotzinger, Susan ; Foster, Jane A ; Kennedy, James L ; Kennedy, Sidney H ; Müller, Daniel J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-futurescience_futuremedicine_10_2217_pgs_15_1363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>cytokines</topic><topic>depression</topic><topic>duloxetine</topic><topic>inflammation</topic><topic>placebo</topic><topic>treatment response</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maciukiewicz, Malgorzata</creatorcontrib><creatorcontrib>Marshe, Victoria S</creatorcontrib><creatorcontrib>Tiwari, Arun K</creatorcontrib><creatorcontrib>Fonseka, Trehani M</creatorcontrib><creatorcontrib>Freeman, Natalie</creatorcontrib><creatorcontrib>Rotzinger, Susan</creatorcontrib><creatorcontrib>Foster, Jane A</creatorcontrib><creatorcontrib>Kennedy, James L</creatorcontrib><creatorcontrib>Kennedy, Sidney H</creatorcontrib><creatorcontrib>Müller, Daniel J</creatorcontrib><jtitle>Pharmacogenomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maciukiewicz, Malgorzata</au><au>Marshe, Victoria S</au><au>Tiwari, Arun K</au><au>Fonseka, Trehani M</au><au>Freeman, Natalie</au><au>Rotzinger, Susan</au><au>Foster, Jane A</au><au>Kennedy, James L</au><au>Kennedy, Sidney H</au><au>Müller, Daniel J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genetic variation in</atitle><jtitle>Pharmacogenomics</jtitle><date>2015-11-01</date><risdate>2015</risdate><volume>16</volume><issue>17</issue><spage>1919</spage><epage>1929</epage><pages>1919-1929</pages><issn>1462-2416</issn><eissn>1744-8042</eissn><abstract>This study investigated polymorphisms of five inflammatory-related genes for association with duloxetine and placebo response in patients with major depression.
Twenty SNPs in
and
were genotyped in major depressive disorder patients treated with either duloxetine (n = 215) or placebo (n = 235) for up to 8 weeks. Treatment response was measured with the Montgomery-Åsberg Depression Rating Scale.
variants rs2066992 and rs10242595 were nominally associated with response to duloxetine (p = 0.047 and p = 0.028, respectively). Notably, the variant rs2066992 was also associated with placebo response (p = 0.026). However, none of our results remained significant after correction for multiple testing.
Our findings tentatively suggest that
variants play a role in duloxetine and placebo response, which warrants further investigation.</abstract><pub>Future Medicine Ltd</pub><doi>10.2217/pgs.15.136</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-2416 |
| ispartof | Pharmacogenomics, 2015-11, Vol.16 (17), p.1919-1929 |
| issn | 1462-2416 1744-8042 |
| language | eng |
| recordid | cdi_futurescience_futuremedicine_10_2217_pgs_15_136 |
| source | PubMed Central |
| subjects | cytokines depression duloxetine inflammation placebo treatment response |
| title | Genetic variation in |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T03%3A30%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-futurescience&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genetic%20variation%20in&rft.jtitle=Pharmacogenomics&rft.au=Maciukiewicz,%20Malgorzata&rft.date=2015-11-01&rft.volume=16&rft.issue=17&rft.spage=1919&rft.epage=1929&rft.pages=1919-1929&rft.issn=1462-2416&rft.eissn=1744-8042&rft_id=info:doi/10.2217/pgs.15.136&rft_dat=%3Cfuturescience%3E10_2217_pgs_15_136%3C/futurescience%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |